Adalimumab for the treatment of Crohn’s disease

INTRODUCTION: Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing-remitting course with trans-mural inflammation of potentially any section of the digestive tract. Adalimumab (ADA) is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassinotti, Andrea, Ardizzone, Sandro, Porro, Gabriele Bianchi
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727899/
https://www.ncbi.nlm.nih.gov/pubmed/19707457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727899/
https://www.ncbi.nlm.nih.gov/pubmed/19707457

Ejemplares similares